haxxiy on 29 June 2021
Here we are at 58% of adults with the first dose and 16% with the second dose, with the aim to rise to 100% and 58%, respectively, by late September.
Since seroprevalence is now above 50%, I expect numbers to fall earlier than that, though, considering how absurdly high antibody titers are in the convalescent after just one dose.
